期刊文献+

红细胞生成素对糖尿病大鼠肾脏保护作用的机制 被引量:4

Renal protection of erythropoietin and its mechanism in diabetic rats
原文传递
导出
摘要 目的观察红细胞生成素(EPO)对糖尿病大鼠的。肾脏保护作用,并探讨其发挥肾脏保护作用的可能机制。方法将实验大鼠随机分为正常对照组(NC组)、糖尿病模型组(DM组)和EPO治疗组(DE组)。药物干预8周后,处死大鼠,检测尿白蛋白排泄率(UAER)、血清肌酐(Scr)、血细胞比容(Hct)。肾组织切片行HE、PAS染色,观察大鼠肾脏病理改变。化学比色法检测肾脏丙二醛(MDA)含量、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)活性及总抗氧化能力(T—AOC)。免疫荧光及Western印迹法检测大鼠肾脏EPO受体(EPOR)的表达。免疫组织化学及Western印迹法检测大鼠肾脏NADPH氧化酶亚基(p47phox)、转化生长因子β1(TGF-β1)、纤连蛋白(FN)的表达。结果EPO可以减轻糖尿病大鼠肾脏病理及功能改变。各组大鼠肾脏均表达EPOR,但表达水平比较差异无统计学意义(P〉0.05)。与NC组相比,DM组大鼠p47phox、TGF-β1、FN蛋白表达增强(均P〈0.01);GSH—Px、SOD活性及T-AOC下降(均P〈0.01);MDA含量增加(P〈0.01)。与DM组相比,DE组大鼠p47phox、TGF-β1、FN蛋白表达减弱(均P〈0.05);GSH—Px、SOD活性及T—AOC升高(均P〈0.01);MDA含量降低(P〈0.01)。结论EPO可通过抑制糖尿病大鼠肾脏氧化应激,降低TGF—β1、FN表达,减轻糖尿病大鼠肾脏病理改变,发挥肾脏保护作用。 Objective To investigate the renoprotective effect of erythropoietin (EPO) in streptozotocin-induced diabetic rats and to explore the possible mechanism. Methods The SD rats were randomly divided into there groups: normal control rats, diabetic, diabetic treated with EPO(NC, DM, DE groups). The rats were sacrificed after 8 weeks treatment. Renal morphology was observed by light microscopy. The expression of erythropoietin receptor (EPOR) in kidney was detected by immunofluorescence and Western blotting. The expression of p47phox, transforming growth factor (TGF) β1 and fibronectin (FN) protein in kidney was detected by immunohistochemistry and Western blotting. The activity of antioxidants including total antioxidant capacity (T-AOC), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and the level of malondialdehyde (MDA) in kidney were also measured. Results EPO treatment notably attenuated renal pathologic and functional changes. The expression of EPOR was found in kidney, but there was no difference among groups (P〉0.05). Compared with normal rats, diabetic rats showed an elevated expression of p47phox, TGF-β1, FN proteins and MDA levels in kidney as well as reduced activities of SOD, GSH-Px and T-AOC (all P〈0.01). Compared with diabetic rats, EPO could decrease the protein expression of p47phox,TGF-β1 and FN in kidney (all P〈0.05). Meanwhile, elevated MDA level in the kidney was decreased as well as decreased SOD, GSH-Px, T-AOC activities were significantly remitted in DE group (all P〈0.01). Conclusion EPO can ameliorate renal damage via the inhibition of oxidative stress and TGF-β1 and FN protein expression in streptozotocin-induced diabetic rats.
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2011年第8期597-601,共5页 Chinese Journal of Nephrology
关键词 糖尿病肾病 红细胞生成素 氧化应激 NADPH氧化酶 Diabetic nephropathies Erythropoietin Oxidative stress NADPH oxidase
  • 相关文献

参考文献14

  • 1Bianchi R, Gilardini A, Rodriguez-Menendez V, et al.Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth. Eur J Cancer, 2007, 43: 710-717.
  • 2Sharples EJ, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol, 2004, 15: 2115-2124.
  • 3Zhang F, Xing J, Liou AK, et al. Enhanced delivery of erythropoietin across the blood- brain barrier for neuroprotection against ischemie neuronal injury. Transl Stroke Res, 2010, 1: 113-121.
  • 4Jaimes EA, Hua P, Tiau RX, et al. Human glomerular endothelium: interplay among glucose, free fatty acids, angiotensin II,and oxidative stress. Am J Physiol Renal Physiol, 2010, 298: F125-F132.
  • 5党建中,贾汝汉,涂亚芳,肖圣顺,丁国华.红细胞生成素对高糖诱导肾小管细胞凋亡的影响[J].中华肾脏病杂志,2010,26(7):537-542. 被引量:8
  • 6Ha H, Hwang IA, Park JH, et al. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract, 2008, 82 Suppl 1: S42-S45.
  • 7Yuan J, Jia R, Bao Y. Beneficial effects of spironolactone on glornerular injury in streptozotocin-induced diabetic rats. J Renin Angiotensin Aldosterone Syst, 2007, 8: 118-126.
  • 8Chen S, Hong SW, Iglesias-de la Cruz MC, et al. The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy. Ren Fail, 2001, 23: 471-481.
  • 9Sharma K, Mcgowan TA. TGF-beta in diabetic kidney disease:role of novel signaling pathways. Cytokine Growth Factor Rev, 2000, 11: 115-125.
  • 10Pantsulaia T. Role of TGF-beta in pathogenesis of diabetic nephropathy. Georgian Med News, 2006: 13-18.

二级参考文献21

  • 1熊晓玲,贾汝汉,杨定平,丁国华.依贝沙坦抑制造影剂诱导的肾小管上皮细胞凋亡[J].中华肾脏病杂志,2006,22(11):682-687. 被引量:16
  • 2包艳,贾汝汉,袁军,李竞,叶迎春,孙永林,王颖.罗格列酮对糖尿病大鼠肾脏保护作用机制的探讨[J].中华肾脏病杂志,2007,23(4):224-229. 被引量:18
  • 3Vasavada N, Agarwal R. Role of oxidative stress in diabetic nephropathy. Adv Chronic Kidney Dis, 2005, 12: 146-154.
  • 4Prabhakar S, Starnes J, Shi S, et al. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol, 2007, 18: 2945-2952.
  • 5Krantz SB. Erythropoietin. Blood, 1991, 77: 419-434.
  • 6Johnson DW, Forman C, Vesey DA. Novel renoprotective actions of erythropoietin: new uses for an old hormone. Nephrology (Carlton), 2006, 11: 306-312.
  • 7Bahhnann FH, de Groot K, Hailer H, et al. Erythropoietin: is it more than correcting anaemia? Nephrol Dial Transplant, 2004, 19: 20-22.
  • 8Johnson DW, Pat B, Vesey DA, et al. Delayed administration of darbepoetin oi: erythropoietin protects against ischaemic acute renal injury and failure. Kidney lnt, 2006, 69: 1806-1813.
  • 9Bianchi R, Buyukakilli B, Brines M, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA, 2004, 101: 823-828.
  • 10Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting etythropoietin analogue darbepoetin alpha persis-tently activates endothelial Akt and attenuates progressive organfailure. Circulation, 2004, 110: 1006-1012.

共引文献7

同被引文献56

  • 1王大海,田道法.益气解毒颗粒配合放射治疗鼻咽癌的临床研究[J].湖南中医学院学报,2006,26(1):36-37. 被引量:12
  • 2彭涛,胡昭,王荣,王群.重组人促红细胞生成素治疗肾性贫血的多中心临床研究[J].中国药房,2007,18(26):2040-2041. 被引量:13
  • 3雷云波,佘艳军,王燕,等.大剂量重组红细胞生成素冲击治疗肾性贫血的疗效观察.医药前沿,2012,2(6):38.
  • 4TEIXEIRA AM,GARRIDO P,SANTOS P,et al.Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure[J].Ren Fail,2010,32(9):1073-1080.
  • 5ZHANG F,XING J,LIOU AK,et al.Enhanced delivery of erythropoietin across the blood-brain barrier for neuroprotection against ischbemic neuronal injury[J].Transl Stroke Res,2010,1:113-121.
  • 6WILLEM G,GERTRUDE J,PETRA J,et al.Renoprotective capacities of non-erythropoietic EPO derivative,ARA290,following renal ischemia/reperfusion injury[J].Transl Med,2013,11:289-293.
  • 7FUNG E,NEMET E.Manipulation of the hepcidin pathway for therapeutic purposes[J].Bibl Haematol,2013,98(11):1667-1676.
  • 8CAMASCHELLA C.Iron and hepcidin:a story of recycling and balance[J].Hematol Am Soc Hematol Educ Program,2013,1(1):1-8.
  • 9MERCADEL L,METZGER M,HAYMANN J,et al.The relation of hepcidin to iron disorders,inflammation and hemoglobin in chronic kidney disease[J].Public Libr Sci,2014,(9)6:1-7.
  • 10KFW M.Hepatic iron overload and hepatocellular carcinoma[J].Liver Cancer,2014,3(1):31-40.

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部